Annual accounts receivable:
$8.30B-$105.00M(-1.25%)Summary
- As of today (May 29, 2025), AZN annual accounts receivable is $8.30 billion, with the most recent change of -$105.00 million (-1.25%) on December 31, 2024.
- During the last 3 years, AZN annual accounts receivable has risen by +$2.27 billion (+37.66%).
- AZN annual accounts receivable is now -1.25% below its all-time high of $8.41 billion, reached on December 31, 2023.
Performance
AZN Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$13.25B(NaN%)Summary
- As of today (May 29, 2025), AZN quarterly accounts receivable is $13.25 billion
- Over the past year, AZN quarterly accounts receivable has increased by +$2.18 billion (+19.67%).
- AZN quarterly accounts receivable is now at all-time high.
Performance
AZN Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
AZN Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.3% | +19.7% |
| 3 y3 years | +37.7% | +52.6% |
| 5 y5 years | +131.6% | +160.8% |
AZN Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -1.3% | +37.7% | at high | +83.7% |
| 5 y | 5-year | -1.3% | +131.6% | at high | +248.1% |
| alltime | all time | -1.3% | +538.0% | at high | +7140.4% |
AZN Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $13.25B(+11.5%) |
| Dec 2024 | $8.30B(-1.2%) | - |
| Sep 2024 | - | $11.88B(+7.5%) |
| Jun 2024 | - | $11.05B(-0.2%) |
| Mar 2024 | - | $11.07B(-2.0%) |
| Dec 2023 | $8.41B(+16.6%) | - |
| Sep 2023 | - | $11.30B(+1.9%) |
| Jun 2023 | - | $11.09B(+7.8%) |
| Mar 2023 | - | $10.29B(+42.7%) |
| Dec 2022 | $7.21B(+19.6%) | $7.21B(-22.8%) |
| Sep 2022 | - | $9.34B(+4.8%) |
| Jun 2022 | - | $8.91B(+2.6%) |
| Mar 2022 | - | $8.68B(+44.0%) |
| Dec 2021 | $6.03B(+58.5%) | $6.03B(-27.0%) |
| Sep 2021 | - | $8.26B(+29.9%) |
| Jun 2021 | - | $6.36B(+1.2%) |
| Mar 2021 | - | $6.28B(+65.0%) |
| Dec 2020 | $3.81B(+6.2%) | $3.81B(-32.9%) |
| Sep 2020 | - | $5.67B(+12.8%) |
| Jun 2020 | - | $5.02B(-1.1%) |
| Mar 2020 | - | $5.08B(+41.7%) |
| Dec 2019 | $3.58B(+19.7%) | $3.58B(-32.1%) |
| Sep 2019 | - | $5.28B(-0.8%) |
| Jun 2019 | - | $5.32B(+0.6%) |
| Mar 2019 | - | $5.29B(+76.6%) |
| Dec 2018 | $3.00B(+6.9%) | $3.00B(-45.6%) |
| Sep 2018 | - | $5.51B(+4.8%) |
| Jun 2018 | - | $5.26B(-3.4%) |
| Mar 2018 | - | $5.44B(+94.3%) |
| Dec 2017 | $2.80B(+8.5%) | $2.80B(-38.3%) |
| Sep 2017 | - | $4.54B(+4.4%) |
| Jun 2017 | - | $4.35B(-7.2%) |
| Mar 2017 | - | $4.69B(+81.4%) |
| Dec 2016 | $2.58B(-44.2%) | $2.58B(-52.6%) |
| Sep 2016 | - | $5.45B(-3.0%) |
| Jun 2016 | - | $5.62B(-4.2%) |
| Mar 2016 | - | $5.87B(+26.6%) |
| Dec 2015 | $4.63B(-2.7%) | $4.63B(-21.2%) |
| Sep 2015 | - | $5.88B(-11.2%) |
| Jun 2015 | - | $6.62B(-1.3%) |
| Mar 2015 | - | $6.70B(+40.8%) |
| Dec 2014 | $4.76B(-13.6%) | $4.76B(-30.1%) |
| Sep 2014 | - | $6.81B(-12.9%) |
| Jun 2014 | - | $7.82B(-8.9%) |
| Mar 2014 | - | $8.58B(+55.6%) |
| Dec 2013 | $5.51B | $5.51B(-24.4%) |
| Sep 2013 | - | $7.29B(+0.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $7.27B(-3.4%) |
| Mar 2013 | - | $7.52B(+32.0%) |
| Dec 2012 | $5.70B(-14.1%) | $5.70B(-28.8%) |
| Sep 2012 | - | $8.00B(+7.2%) |
| Jun 2012 | - | $7.46B(-12.3%) |
| Mar 2012 | - | $8.51B(+28.4%) |
| Dec 2011 | $6.63B(+6.1%) | $6.63B(-20.2%) |
| Sep 2011 | - | $8.31B(-0.1%) |
| Jun 2011 | - | $8.32B(-2.0%) |
| Mar 2011 | - | $8.49B(+36.0%) |
| Dec 2010 | $6.25B(+8.0%) | $6.25B(-19.2%) |
| Sep 2010 | - | $7.74B(+5.9%) |
| Jun 2010 | - | $7.31B(-10.1%) |
| Mar 2010 | - | $8.13B(+40.5%) |
| Dec 2009 | $5.78B(-20.4%) | $5.78B(-27.8%) |
| Sep 2009 | - | $8.01B(+8.8%) |
| Jun 2009 | - | $7.36B(+3.3%) |
| Mar 2009 | - | $7.13B(-1.9%) |
| Dec 2008 | $7.26B(+36.3%) | $7.26B(+1.1%) |
| Sep 2008 | - | $7.18B(-2.1%) |
| Jun 2008 | - | $7.33B(+4.0%) |
| Mar 2008 | - | $7.05B(+32.4%) |
| Dec 2007 | $5.33B(+24.2%) | $5.33B(-18.0%) |
| Sep 2007 | - | $6.49B(+3.7%) |
| Jun 2007 | - | $6.26B(+0.4%) |
| Mar 2007 | - | $6.24B(+45.5%) |
| Dec 2006 | $4.29B(-10.3%) | $4.29B(+558.7%) |
| Sep 2006 | - | $651.00M(+138.5%) |
| Jun 2006 | - | $273.00M(-94.3%) |
| Dec 2005 | $4.78B(+33.1%) | $4.78B(+2496.7%) |
| Sep 2005 | - | $184.00M(-8.5%) |
| Jun 2005 | - | $201.00M(+9.8%) |
| Mar 2005 | - | $183.00M(-94.9%) |
| Dec 2004 | $3.59B(+12.1%) | $3.59B(-28.0%) |
| Sep 2004 | - | $4.99B(+55.7%) |
| Dec 2003 | $3.20B(+21.1%) | $3.20B(+21.1%) |
| Dec 2002 | $2.65B(+10.8%) | $2.65B(+10.8%) |
| Dec 2001 | $2.39B(-10.4%) | $2.39B(-10.4%) |
| Dec 2000 | $2.66B(+66.3%) | $2.66B(+66.3%) |
| Dec 1997 | $1.60B(+0.0%) | $1.60B(+0.0%) |
| Dec 1996 | $1.60B(+5.7%) | $1.60B(+5.7%) |
| Dec 1995 | $1.51B(+8.2%) | $1.51B(+8.2%) |
| Dec 1994 | $1.40B(-1.1%) | $1.40B(-1.1%) |
| Dec 1993 | $1.41B(+8.7%) | $1.41B |
| Dec 1992 | $1.30B(-10.8%) | - |
| Dec 1991 | $1.46B(-10.7%) | - |
| Dec 1990 | $1.63B | - |
FAQ
- What is AstraZeneca annual accounts receivable?
- What is the all time high annual accounts receivable for AstraZeneca?
- What is AstraZeneca annual accounts receivable year-on-year change?
- What is AstraZeneca quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for AstraZeneca?
- What is AstraZeneca quarterly accounts receivable year-on-year change?
What is AstraZeneca annual accounts receivable?
The current annual accounts receivable of AZN is $8.30B
What is the all time high annual accounts receivable for AstraZeneca?
AstraZeneca all-time high annual accounts receivable is $8.41B
What is AstraZeneca annual accounts receivable year-on-year change?
Over the past year, AZN annual accounts receivable has changed by -$105.00M (-1.25%)
What is AstraZeneca quarterly accounts receivable?
The current quarterly accounts receivable of AZN is $13.25B
What is the all time high quarterly accounts receivable for AstraZeneca?
AstraZeneca all-time high quarterly accounts receivable is $13.25B
What is AstraZeneca quarterly accounts receivable year-on-year change?
Over the past year, AZN quarterly accounts receivable has changed by +$2.18B (+19.67%)